Fatemeh Shojaeian

Fatemeh Shojaeian

Auto-generated profile, based on publicly available information

Fatemeh Shojaeian

Sidney Kimmel Comprehensive Cancer Research Center Johns Hopkins School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HHHamidreza Hatamabadi
Hamidreza Hatamabadi
TSTahereh Sabaghian
Tahereh Sabaghian
ASAmir Sadeghi
Amir Sadeghi
KHKamran Heidari
Kamran Heidari
SSSeyed Amir Ahmad Safavi-Naini
Seyed Amir Ahmad Safavi-Naini
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Background. The outbreak of coronavirus disease 2019 (COVID‐19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR. Methods. This observational cohort study was performed from 20th March 2020 to 18th March 2021 in three tertiary educational hospitals in Tehran, Iran. All patients were admitted based on the WHO, CDC, and Iran’s National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, clinical profile, outcomes of disease, and finding the predictors of death due to COVID‐19. Results. Of all 5318 participants, the median age was 60.0 years, and 57.2% of patients were male. The most significant comorbidities were hypertension and diabetes mellitus. Cough, dyspnea, and fever were the most dominant symptoms. Results showed that ICU admission, elderly age, decreased consciousness, low BMI, HTN, IHD, CVA, dialysis, intubation, Alzheimer disease, blood injection, injection of platelets or FFP, and high number of comorbidities were associated with a higher risk of death related to COVID‐19. The trend of CFR was increasing (WPC: 1.86) during weeks 25 to 51. Conclusions. Accurate detection of predictors of poor outcomes helps healthcare providers in stratifying patients, based on their risk factors and healthcare requirements to improve their survival chance.

25 October 2025 in Small
Verified
Journal Article
Open access
Marzieh Ramezani FaraniMarzieh Ramezani Farani
Marzieh Ramezani Farani
Ashkan ZandiAshkan Zandi
Ashkan Zandi
FSFatemeh Shojaeian
Fatemeh Shojaeian
Mingzhen ZhangMingzhen Zhang
Mingzhen Zhang
DKDanial Khorsandi
Danial Khorsandi
YHYun Suk Huh
Yun Suk Huh
Carbon‐based nanomaterials (CBNs), including graphene oxide (GO), carbon nanospheres (CNSs), carbon nitrides (CNs), carbon nanotubes (CNTs), carbon dots (CDs), nanoporous carbon, and nanocomposites, possess exceptional thermal, mechanical, electrical, and optical properties with highly versatile surface chemistries. Their tunable size, shape, and surface functionalities facilitate strong π–π interactions and semiconductor‐like behavior, enabling efficient light absorption and intimate biomolecular interfacing. These attributes have positioned CBNs as leading candidates in biomedical engineering, inspiring biomimetic designs that integrate organic and inorganic functions within unified architectures. This review highlights recent advances in the use of CBNs for next‐generation biosensing and theranostics. Approaches such as physicochemical engineering, deoxyribonucleic acid (DNA) origami templating, peptide‐ or enzyme‐assisted assembly, polysaccharide anchoring, and lipid modification have enhanced their biocompatibility, selectivity, and catalytic activity. Innovations in fluorescence switching, aptamer–CNT photophysics, and spacer‐controlled energy transfer enable ultra‐sensitive detection of metal ions, metabolites, neurotransmitters, pathogens, drugs, and cancer biomarkers. Furthermore, integrated CBN‐based platforms, including field‐effect transistors and laser‐scribed graphene electrodes, demonstrate capabilities for single‐virus or single‐cell diagnostics and responsive therapeutic intervention. Finally, translational challenges related to scalable synthesis, biosafety, regulatory harmonization, and public acceptance are discussed, and interdisciplinary strategies combining flexible electronics, organ‐on‐chip models, and AI‐guided design to advance clinical translation of CBN‐enabled precision diagnostics and personalized theranostics are proposed.

1 May 2025 in Cancer Research Communications
Verified
Journal Article
Open access
BNBernat Navarro-Serer
Bernat Navarro-Serer
MWMaria F. Wissler
Maria F. Wissler
BGBrandi K. Glover
Brandi K. Glover
MLMichael G. Lerner
Michael G. Lerner
HOHarsh H. Oza
Harsh H. Oza
LWLaura D. Wood
Laura D. Wood
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with dismal prognosis. PDAC develops in a hypoxic environment in which cells adapt and activate processes to allow survival under low-oxygen conditions, some of which may enhance the ability of cancer cells to invade locally or metastasize distantly. Using human PDAC organoids, we determined that hypoxia consistently enhanced invasion across 11 patient-derived models. Using RNA sequencing of hypoxic invasive organoids (compared with matched invasive normoxic organoids from the same patients), we identified prolyl 4-hydroxylase subunit alpha 1 (P4HA1) as a potential regulator of PDAC invasion in hypoxia. Leveraging publicly available datasets from human tissue, we determined that P4HA1 is more highly expressed in PDAC compared with normal pancreatic tissue and that high P4HA1 expression correlates with poor patient prognosis. To further interrogate the role of P4HA1 in invasion of hypoxic patient-derived organoids, we quantified invasion in organoids modified to knockdown or overexpress P4HA1, demonstrating that P4HA1 is necessary for hypoxia-enhanced invasion and sufficient to increase invasion in normoxia in PDAC organoids. Our results identify P4HA1 as a driver of PDAC organoid invasion in hypoxia. Significance: This study demonstrates that hypoxia increases invasion across a cohort of human pancreatic cancer organoids and identifies the collagen-modifying enzyme P4HA1 as a driver of hypoxia-enhanced invasion. These results characterize a molecular mechanism by which the microenvironment alters tumor cell behavior and underscore new strategies to inhibit invasion.

5 March 2025 in Health Science Reports
Verified
Journal Article
Open access
ASAryan Salahi‐Niri
Aryan Salahi‐Niri
PZPaniz Zarand
Paniz Zarand
NMNegar Mansouri
Negar Mansouri
PRParvaneh Rastgou
Parvaneh Rastgou
OYOmid Yazdani
Omid Yazdani
SSSeyed Amir Ahmad Safavi-Naini
Seyed Amir Ahmad Safavi-Naini
Background and Aims: Pancreatic cancer is an aggressive malignancy with poor prognosis and limited treatment options. Chemotherapy remains a primary therapeutic approach, but patient responses vary significantly, emphasizing the need for reliable biomarkers. This review explores the potential role of proliferative markers, including Ki‐67, PCNA, Cyclin D1, and PHH3, as predictive and prognostic indicators in pancreatic cancer management, aiming to enhance personalized treatment strategies.Methods: We conducted a narrative review by searching Scopus, PubMed, and Google Scholar for studies focusing on Ki‐67, PCNA, Cyclin D1, and PHH3 in relation to pancreatic cancer and chemotherapy. The literature was reviewed to evaluate the role of these markers in predicting chemotherapy response, tumor progression, and overall patient survival.Results: The review highlights the clinical significance of these markers. Ki‐67 and PCNA are associated with cell proliferation, while Cyclin D1 regulates cell cycle progression and PHH3 is linked to mitotic activity. High expression levels of these markers often correlate with increased tumor aggressiveness and poorer patient outcomes. Moreover, they show promise in predicting chemotherapy response, which can inform tailored therapeutic strategies. However, challenges remain, including standardization of detection methods and determination of optimal cutoff values.Conclusion: Proliferative markers such as Ki‐67, PCNA, Cyclin D1, and PHH3 hold potential as predictive and prognostic tools in pancreatic cancer management. Their integration into clinical practice could improve the accuracy of treatment decisions and enhance patient outcomes. Further research and validation are necessary to overcome existing challenges and optimize their application in personalized oncology.

8 April 2025 in Health Science Reports
Verified
Journal Article
Open access
ASAryan Salahi‐Niri
Aryan Salahi‐Niri
PZPaniz Zarand
Paniz Zarand
FSFatemeh Shojaeian
Fatemeh Shojaeian
NMNegar Mansouri
Negar Mansouri
OYOmid Yazdani
Omid Yazdani
BJBehnaz Jahanbin
Behnaz Jahanbin
Background and Aims: Breast cancer is the most common cancer and a leading cause of cancer‐related death among women globally. Determining which patients will benefit from chemotherapy remains challenging. Proliferative markers such as Ki‐67, mini chromosome maintenance (MCM) proteins, and proliferating cell nuclear antigen (PCNA) offer valuable insights into tumor growth and treatment response. This review evaluates their clinical roles, with a focus on chemotherapy implications and emerging digital pathology techniques for marker quantification.Methods: A narrative review was conducted by searching PubMed, Scopus, and Google Scholar for studies related to Ki‐67, MCM, PCNA, breast cancer, and chemotherapy. Studies were thematically categorized into five areas. A bibliometric analysis of publications from 2000 to April 2023 was performed using the Bibliometrix R package and VOSviewer to assess research trends and thematic evolution.Results: Eighty studies were included in the narrative synthesis. Ki‐67 is the most commonly used marker, particularly useful in predicting response to neoadjuvant chemotherapy (NAC). MCM proteins show promise for identifying proliferative potential across tumor grades, while PCNA is associated with aggressive tumor features and poor prognosis. Post‐chemotherapy changes in Ki‐67 levels are linked to survival outcomes. Bibliometric analysis revealed a shift in research focus from basic mechanisms to clinical applications and digital quantification.Conclusion: Proliferative markers play an essential role in breast cancer management. Ki‐67 remains a key predictor of chemotherapy response, while MCM and PCNA offer complementary prognostic insights. Integration of these markers with digital pathology and AI‐driven tools may enhance diagnostic accuracy and personalized treatment strategies. Standardization of assessment methods is crucial for broader clinical application.

27 February 2022 in medRxiv
Verified
Preprint
Open access
PDF file
YFYeganeh Farsi
Yeganeh Farsi
FSFatemeh Shojaeian
Fatemeh Shojaeian
SSSeyed Amir Ahmad Safavi-Naini
Seyed Amir Ahmad Safavi-Naini
MHMohammadjavad Honarvar
Mohammadjavad Honarvar
BMBenyamin Mohammadzadeh
Benyamin Mohammadzadeh
Mohammad Javad NasiriMohammad Javad Nasiri
Mohammad Javad Nasiri
Introduction Coronavirus Disease 2019 (COVID -19) pandemic challenged the healthcare system drastically, and it was concomitant with a remarkable decline in surgeries and modified routine care of patients worldwide. This systematic review and meta-analysis aimed to compare the surgical complications before COVID -19 (Pre-COVID) and after COVID -19 (post-COVID) appearance using the Clavien-Dindo classification (CDC). Methods between January 1, 2019, to November 3, 2021, we performed a comprehensive search in PubMed/Medline and Scopus for studies reporting the postoperative complications based on/transformable to CDC. Result From 909 screened articles, 34 studies were included for systematic review. Among included articles, 11 were eligible for meta-analysis. Nineteen thousand one hundred thirty-seven patients (pre-COVID: 3522, post-COVID: 15615) were included, mostly undergoing elective surgeries (86.32%). According to CDC classification, there were no significant change between pre-COVID and post-COVID for grade 1 (Odds ratio (OR) and 95% confidence interval (95-CI): 0.99, 0.60-1.63, p=0.96), grade 2 (OR and 95-CI: 0.65, 0.42-1.01, p = 0.055), grade 3 (OR and 95-CI: 0.86, 0.48-1.57, p=0.64), grade 4 (OR and 95-CI: 0.85, 0.46-1.57, p =0.60). However, the postoperative mortality was lower before the COVID -19 outbreak (OR and 95-CI: 0.51, 0.27-0.95, p= 0.035). The included studies for systematic review and meta-analysis had a low risk of bias and unsignificant publication bias. Conclusion Although delivering routine surgery was challenging, the postoperative complications during the pandemic remained identical to the pre-pandemic era. The stricter patient selection tending to choose more critical states and more advanced clinical stages of the operated patients may explain some extent of higher mortality during the pandemic. Adopting preventive strategies helped deliver surgeries during the outbreak of COVID -19 while limiting the capacity of operations and admissions.